MA67325B1 - Dérivés de naphtyridinone pour le traitement d'une maladie ou d'un trouble - Google Patents

Dérivés de naphtyridinone pour le traitement d'une maladie ou d'un trouble

Info

Publication number
MA67325B1
MA67325B1 MA67325A MA67325A MA67325B1 MA 67325 B1 MA67325 B1 MA 67325B1 MA 67325 A MA67325 A MA 67325A MA 67325 A MA67325 A MA 67325A MA 67325 B1 MA67325 B1 MA 67325B1
Authority
MA
Morocco
Prior art keywords
disorder
disease
treatment
naphthyridinone derivatives
naphthyridinone
Prior art date
Application number
MA67325A
Other languages
English (en)
Inventor
Yu GAI
Atwood Kim Cheung
Donglei Liu
Stefan Peukert
Heng GE
Xingjuan CHANG
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA67325B1 publication Critical patent/MA67325B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un composé de formule (I) ou un sel pharmaceutiquement acceptable de celui-ci, A, R1 et R3 étant tels que décrits dans la description, ainsi que des compositions et des procédés d'utilisation de tels composés.
MA67325A 2021-11-23 2022-11-21 Dérivés de naphtyridinone pour le traitement d'une maladie ou d'un trouble MA67325B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163282492P 2021-11-23 2021-11-23
CN2022128601 2022-10-31
EP22817365.4A EP4436662B1 (fr) 2021-11-23 2022-11-21 Dérivés de naphtyridinone pour le traitement d'une maladie ou d'un trouble
PCT/IB2022/061218 WO2023094965A1 (fr) 2021-11-23 2022-11-21 Dérivés de naphtyridinone pour le traitement d'une maladie ou d'un trouble

Publications (1)

Publication Number Publication Date
MA67325B1 true MA67325B1 (fr) 2025-11-28

Family

ID=84370237

Family Applications (1)

Application Number Title Priority Date Filing Date
MA67325A MA67325B1 (fr) 2021-11-23 2022-11-21 Dérivés de naphtyridinone pour le traitement d'une maladie ou d'un trouble

Country Status (28)

Country Link
US (2) US12084442B2 (fr)
EP (2) EP4436662B1 (fr)
JP (2) JP7826477B2 (fr)
KR (1) KR20240110040A (fr)
CN (1) CN118382623A (fr)
AR (1) AR127698A1 (fr)
AU (1) AU2022396087A1 (fr)
CA (1) CA3235682A1 (fr)
CL (1) CL2024001524A1 (fr)
CO (1) CO2024006398A2 (fr)
CR (1) CR20240216A (fr)
DK (1) DK4436662T3 (fr)
DO (1) DOP2024000096A (fr)
EC (1) ECSP24038829A (fr)
ES (1) ES3054973T3 (fr)
FI (1) FI4436662T3 (fr)
HR (1) HRP20251558T1 (fr)
IL (1) IL312689A (fr)
JO (1) JOP20240119A1 (fr)
LT (1) LT4436662T (fr)
MA (1) MA67325B1 (fr)
MX (1) MX2024006176A (fr)
PE (1) PE20241328A1 (fr)
PL (1) PL4436662T3 (fr)
PT (1) PT4436662T (fr)
RS (1) RS67492B9 (fr)
UY (1) UY40025A (fr)
WO (1) WO2023094965A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL324432A (en) * 2023-05-24 2026-01-01 Novartis Ag Naphthyridinone derivatives for the treatment of a disease or disorder

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA92121A (fr) 1904-11-07 1905-03-14 William Waid Paddock Filtre a pression
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
ES2113879T3 (es) 1990-01-24 1998-05-16 Douglas I Buckley Analogos de glp-1 utiles para el tratamiento de diabetes.
EP0618803A4 (fr) 1991-12-19 1995-03-22 Southwest Found Biomed Res Polypeptide inhibant la proteine de transfert aux esters de cholesteryl, anticorps contre le polypeptide synthetique et traitements prophylactiques et therapeutiques anti-atherosclerose.
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6544974B2 (en) 1999-09-23 2003-04-08 G.D. Searle & Co. (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesteryl ester transfer protein activity
PE20020082A1 (es) 2000-04-12 2002-02-21 Novartis Ag Composicion farmaceutica que comprende un inhibidor de aldosterona-sintasa y un antagonista del receptor de angiotensina ii (at1)
WO2004078163A2 (fr) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Compositions pharmaceutiques a base d'un co-cristal
ES2270143T3 (es) 2002-08-07 2007-04-01 Novartis Ag Compuestos organicos como agentes para el tratamiento de condiciones mediadas por aldosterona.
ES2305520T3 (es) 2002-11-18 2008-11-01 Novartis Ag Derivados de imidazo(1,5a)piridina y metodos para tratar enfermedades mediadas por aldosterona.
BRPI0508966A (pt) 2004-03-26 2007-08-21 Lilly Co Eli composto, composição farmacêutica, e, uso de um composto
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
US7612088B2 (en) 2004-05-28 2009-11-03 Speedel Experimenta Ag Heterocyclic compounds and their use as aldosterone synthase inhibitors
US20080076794A1 (en) 2004-05-28 2008-03-27 Peter Herold Heterocyclic Compounds And Their Use As Aldosterone Synthase Inhibitors
AR049126A1 (es) 2004-05-28 2006-06-28 Speedel Experimenta Ag Derivados de 5, 6, 7, 8 - tetrahidroimidazo[1,5a]piridina con actividad inhibitoria de la aldosterona sintasa, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del hiperaldosterismo y del sindrome de cushing.
AR049711A1 (es) 2004-07-09 2006-08-30 Speedel Experimenta Ag Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso
TW200716105A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Imidazole compounds
TW200716634A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
TW200804378A (en) 2005-12-09 2008-01-16 Speedel Experimenta Ag Organic compounds
CN101415803B (zh) 2006-04-04 2012-10-24 大阳日酸株式会社 甲烷分离方法、甲烷分离装置以及甲烷利用系统
TW200808812A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808813A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
EP1886695A1 (fr) 2006-06-27 2008-02-13 Speedel Experimenta AG Combinaisons pharmacéutiques avec inhibiteurs de l'aldosterone synthase et antagonistes du recepteur de glucocorticoides où inhibiteurs de la synthese de cortisol où antagonistes du facteur de libération de la corticotropine
WO2008027284A1 (fr) 2006-08-25 2008-03-06 Novartis Ag Dérivés d'imidazole fusionnés destinés à traiter les troubles médiés par l'aldostérone synthase et/ou par 11-beta-hydroxylase et/ou aromatase
WO2008076862A2 (fr) 2006-12-18 2008-06-26 Novartis Ag Composés organiques
EA200900811A1 (ru) 2006-12-18 2009-12-30 Новартис Аг Имидазолы в качестве ингибиторов альдостеронсинтазы
KR20090090395A (ko) 2006-12-18 2009-08-25 노파르티스 아게 4-이미다졸릴-1,2,3,4-테트라히드로퀴놀린 유도체 및 알도스테론/11-베타-히드록실라제 억제제로서의 그의 용도
AR066691A1 (es) 2007-03-29 2009-09-09 Speedel Experimenta Ag Compuestos espiro heterociclicos derivados de imidazol. composiciones farmaceuticas.
JP2015504923A (ja) 2012-01-27 2015-02-16 ギリアード サイエンシーズ, インコーポレイテッド 後期ナトリウムイオンチャネル遮断剤およびカリウムイオンチャネル遮断剤を使用する併用療法
JOP20190086A1 (ar) * 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
EP3801504A4 (fr) * 2018-06-11 2022-07-27 Northeastern University Ligands sélectifs pour la modulation des canaux girk
MX2022010957A (es) 2020-03-03 2023-01-24 Twentyeight Seven Inc Compuestos que se dirigen a las proteínas de unión al arn o a las proteínas modificadoras del arn.
WO2022074567A1 (fr) 2020-10-06 2022-04-14 Novartis Ag Compositions pharmaceutiques comprenant des dérivés de naphtyridinone et leur utilisation dans le traitement de l'arythmie

Also Published As

Publication number Publication date
EP4436662B1 (fr) 2025-09-17
AR127698A1 (es) 2024-02-21
AU2022396087A1 (en) 2024-04-11
PL4436662T3 (pl) 2026-02-16
DK4436662T3 (da) 2025-12-22
US12084442B2 (en) 2024-09-10
CL2024001524A1 (es) 2024-11-08
IL312689A (en) 2024-07-01
JP2024543107A (ja) 2024-11-19
CR20240216A (es) 2024-07-01
ES3054973T3 (en) 2026-02-09
TW202329949A (zh) 2023-08-01
JP2026102627A (ja) 2026-06-23
CN118382623A (zh) 2024-07-23
CO2024006398A2 (es) 2024-07-18
JOP20240119A1 (ar) 2024-05-23
US20230203032A1 (en) 2023-06-29
RS67492B1 (sr) 2025-12-31
UY40025A (es) 2023-06-15
LT4436662T (lt) 2025-12-29
CA3235682A1 (fr) 2023-06-01
PE20241328A1 (es) 2024-06-26
MX2024006176A (es) 2024-06-11
KR20240110040A (ko) 2024-07-12
WO2023094965A1 (fr) 2023-06-01
DOP2024000096A (es) 2024-06-30
FI4436662T3 (fi) 2025-12-12
EP4656240A1 (fr) 2025-12-03
RS67492B9 (sr) 2026-02-27
HRP20251558T1 (hr) 2026-01-16
US20250214989A1 (en) 2025-07-03
JP7826477B2 (ja) 2026-03-09
PT4436662T (pt) 2025-12-16
ECSP24038829A (es) 2024-06-28
EP4436662A1 (fr) 2024-10-02

Similar Documents

Publication Publication Date Title
MX2025000642A (es) Compuestos macrociclicos para el tratamiento de cancer
MX2023001379A (es) Derivados de piperidin-1-il-n-piridina-3-il-2-oxoacet amida utiles para el tratamiento de canceres deficientes en mtap y/o que acumulan mt a.
MX2024000299A (es) Compuestos antivirales.
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
CR20240147A (es) Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento del linfoma de linfocitos t
PH12021552482A1 (en) Compounds targeting prmt5
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2009003874A (es) Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos.
MX2022008487A (es) Degradadores de smarca2-vhl.
MX2020012827A (es) Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes.
PH12021552513A1 (en) Pyrrole compounds
PH12021552533A1 (en) Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease
MX2025010256A (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
MX2021012491A (es) Agentes antiproliferativos para el tratamiento de la hipertensión arterial pulmonar.
EP4316504A3 (fr) Composés
MX2022010957A (es) Compuestos que se dirigen a las proteínas de unión al arn o a las proteínas modificadoras del arn.
MX2024002409A (es) Terapias contra el cancer.
PH12021552953A1 (en) Tricyclic compounds
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
MX379704B (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
JOP20220082A1 (ar) مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
CR20250290A (es) Inhibidores de prmt5-mta
GEAP202516749A (en) Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
JOP20240119A1 (ar) مشتقات نافثيريدينون لمعالجة مرض أو اضطراب
CR20220231A (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria